We are living in a golden age of technology—an age in which chronic diseases will be cured and future generations will live far healthier and longer lives.

Advances in AI are enhancing our intelligence— synthesizing information, recognizing complex patterns and making predictions on a scale and at a speed beyond human capability. Pair that with the incredible work in laboratories around the world increasing our understanding of genomics, and the potential to improve our health is limitless.

Now, imagine that power applied to some of the biggest challenges we face. Like breast cancer. Today, 1 in 8 women will be diagnosed with a form of breast cancer during their lifetime—that's 1 in 8 women who we know, who we love, who are at risk of dying from this disease.

What if we could use technology to identify the markers that could help us detect this deadly disease earlier? What if we could use health data to understand a woman's unique genetic risks to personalize her screening?

My friend, Dr. Laura Esserman, a pioneer in breast cancer research at the University of California, San Francisco (UCSF), and her team are working to take on that challenge.

Today, breast cancer screening guidelines treat every woman the same, assuming they all share the same risk. And while mammograms are one of our best methods of detection, the recommendations are confusing and dated, based on decades old science. The health community is torn on how to advise women, operating with no globally accepted standard.

With the UCSF Wisdom Movement research project, they want to bring today's guidelines in line with today's science and technology by showing that breast cancer screening can be more effective when we don’t treat women as a demographic, but when it’s more personalized and treats each woman's history and body as unique.

It aims to bring a personalized approach to breast cancer screening by learning from a trial of over 100,000 women. Mapping gene variability to determine a woman’s unique genetic risk for breast cancer, as well as factoring in differences in cancer biology, environment, lifestyle, and clinical intervention performance, the trial is paving the way for a transition from generalized care to personalized medicine. That could mean earlier detection, which means lives saved.

At Salesforce, we support her work because we know that equipped with the latest technology, Dr. Esserman and her team can drive the next generation of medicine. By working together, we can be smarter and more effective about how we take on this disease.

But we can't get there alone. To achieve our goal of 100K strong — bringing in 100,000 women and $100,000 — we need our incredible community to join the Movement so we can all #getwise about breast cancer. That's why Wisdom is going to be on-site at Dreamforce, where they'll be enrolling eligible women in the study and encouraging all attendees to learn about and join the Movement. Visit them at the Customer Success Expo in Moscone South.

Not going to be at Dreamforce? That's ok — you can still help the cause in a couple of ways: donate today by texting Wisdom to 71777 — your donations will help us provide women with personalized risk assessments, genetic testing, and high-risk counseling; or visit wisdom.force.com to see if you or a woman in your life is eligible to join the study.

Join the movement to show just how limitless we can be.